Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 68.4%

Neg 68.4% Neu 0% Pos 0%

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $4 to $3.